BiondVax to Present at Universal Influenza Vaccines Conference

NESS ZIONA, Israel, April 12, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of the universal flu vaccine candidate M-001, reported today it will present at the Universal Influenza Vaccines 2018 Conference. The conference is being held on April 16-18 at the University of Lausanne in Switzerland.

Dr. Tamar Ben-Yedidia, BiondVax's Chief Science Officer (CSO), will provide an overview of the Company's clinical development achievements and plans, with a focus on:

  • Results of a Phase 2b trial conducted in collaboration with the EU-sponsored UNISEC* consortium
  • Update of an ongoing United States NIH-sponsored Phase 2 trial
  • Plans for the pivotal, clinical efficacy Phase 3 trial, expected to begin in 2018

Details of Dr. Ben-Yedidia's talk:
Getting closer to the market: M-001 universal flu vaccine starting pivotal Phase 3 Trial
Date: Monday, April 16, 2018
Time: 4:00pm (GMT+2)
Location: CHUV, University of Lausanne, Lausanne, Switzerland

Dr. Ron Babecoff, CEO, and Dr. Ben-Yedidia are serving on the conference's Scientific Advisory Panel and will be available for meetings.

* Research supporting UNISEC activities received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement n°602012.

About BiondVax Pharmaceuticals Ltd
BiondVax is an advanced clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. BiondVax is traded on NASDAQ: BVXV. Please visit

Back to news